Tave AK - Search Results

1

Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation.

Goehring EL Jr, Bohn RL, Pezzullo J, Tave AK, Jones JK, Bozzi S, Tamayo RCSG, Sicignano N, Naccarelli GV. Goehring EL Jr, et al. Among authors: tave ak. Am J Cardiol. 2020 Nov 15;135:77-83. doi: 10.1016/j.amjcard.2020.08.026. Epub 2020 Aug 27. Am J Cardiol. 2020. PMID: 32861738

2

Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics.

Tave A, Goehring E, Desai V, Wu C, Bohn RL, Tamayo SG, Sicignano N, Juhaeri J, Jones JK, Weiss SR. Tave A, et al. Pharmacoepidemiol Drug Saf. 2021 Oct;30(10):1353-1359. doi: 10.1002/pds.5233. Epub 2021 May 4. Pharmacoepidemiol Drug Saf. 2021. PMID: 33730412 Free PMC article.

3

Long-term risk of reproductive cancer among Vietnamese women using the quinacrine hydrochloride pellet system vs. intrauterine devices or tubal ligation for contraception.

Jones JK, Tave A, Pezzullo JC, Kardia S, Lippes J. Jones JK, et al. Eur J Contracept Reprod Health Care. 2017 Apr;22(2):123-130. doi: 10.1080/13625187.2017.1285880. Epub 2017 Feb 13. Eur J Contracept Reprod Health Care. 2017. PMID: 28256916

4

Long-term risk of hysterectomy and ectopic pregnancy among Vietnamese women using the quinacrine hydrochloride pellet system vs. intrauterine devices or tubal ligation for contraception.

Jones JK, Tave A, Pezzullo JC, Kardia S, Lippes J. Jones JK, et al. Eur J Contracept Reprod Health Care. 2018 Apr;23(2):105-115. doi: 10.1080/13625187.2018.1449823. Epub 2018 Apr 23. Eur J Contracept Reprod Health Care. 2018. PMID: 29683010

5

Prevalence of pediatric dyslipidemia: comparison of a population-based claims database to national surveys.

Li J, Motsko SP, Goehring EL Jr, Tave A, Pezzullo JC, Jones JK. Li J, et al. Pharmacoepidemiol Drug Saf. 2010 Oct;19(10):1031-40. doi: 10.1002/pds.1982. Pharmacoepidemiol Drug Saf. 2010. PMID: 20602343

6

Liver, renal, genitourinary and diabetic ketoacidosis risks among new users of empagliflozin versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Post-authorization safety study based on multinational cohorts.

Rebordosa C, Thomsen RW, Tave AK, Madsen M, Beachler DC, Martinez D, Garcia-Esteban R, Plana E, Tormos A, Farsani SF, Perez-Gutthann S, Pladevall-Vila M. Rebordosa C, et al. Among authors: tave ak. Diabetes Obes Metab. 2024 Apr;26(4):1291-1304. doi: 10.1111/dom.15429. Epub 2024 Jan 17. Diabetes Obes Metab. 2024. PMID: 38234181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6 results

Search Page